Predict your next investment

Tempus company logo
Corporation
HEALTHCARE | Biotechnology
tempus.com

See what CB Insights has to offer

Competitors

23

Business Relationships

10

Tempus Competitors & Alternatives

23 Competitors

Tempus has 23 competitors. Tempus's competitors are RootPath Genomics, Strata Oncology, Sema4, Lunit, Helix and more.

Latest Funding

Companies

Investment Stage

Total Funding

Mosaic
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

Location

9/7/2021

Series B

$68M

Massachusetts

7/28/2021

Series C

$133M

Michigan

7/22/2021

Reverse Merger

$241M

Connecticut

7/19/2021

Series C - II

$74.87M

000

South Korea

6/3/2021

Series C

$468M

California

3/22/2021

Series E

$259.18M

000

California

2/23/2021

Series C - II

$73M

China

2/2/2021

Series G

$169.5M

000

California

1/11/2021

Series A

$53M

China

Latest Funding

9/7/2021

7/28/2021

7/22/2021

7/19/2021

6/3/2021

3/22/2021

2/23/2021

2/2/2021

1/11/2021

Companies

Investment Stage

Series B

Series C

Reverse Merger

Series C - II

Series C

Series E

Series C - II

Series G

Series A

Total Funding

$68M

$133M

$241M

$74.87M

$468M

$259.18M

$73M

$169.5M

$53M

Mosaic

000

000

000

Location

Massachusetts

Michigan

Connecticut

South Korea

California

California

China

California

China

Tempus Partners & Customers

10 Partners and customers

Tempus has 10 strategic partners and customers. Tempus recently partnered with Rain Therapeutics on June 6, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

6/3/2021

Client

Rain Therapeutics

United States

Rain Therapeutics Announces Collaboration With Tempus For Genomic Analysis In Planned MDM2-Amplified Phase 2 Basket Trial Of RAIN-32

NEWARK , Calif. , June 03 , 2021 -- Rain Therapeutics Inc. , a clinical-stage company developing precision oncology therapeutics , today announced a master program and a genomic analysis platform agreement for comprehensive genomic profiling tests utilizing artificial intelligence and precision medicine company Tempus ' genomic analysis platform .

2

5/17/2021

Client

Zentalis Pharmaceuticals

United States

May 17, 2021 at 7:00 AM EDT. Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update.

Zentera Therapeutics , Zentalis Pharmaceuticals , Inc. ' majority-owned joint venture , filed four Clinical Trial Applications and three have been approved in China to date for ZN-c5 , ZN-c3 , and ZN-c3 in combination .

1

3/15/2021

Partner

Community Health Network

United States

Community Virtual Care visits available 24/7. COVID-19: Care Options, Visitor Policies & Testing. Community Health Network collaborates with Tempus to personalize cancer care, improve patient health through genomics testing

Community Health Network announced today it is collaborating with Tempus , a leader in precision medicine and artificial intelligence , to improve patient health and outcomes through genomic testing .

2

2/25/2021

Client

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

2/25/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

6/3/2021

5/17/2021

3/15/2021

2/25/2021

2/25/2021

Type

Client

Client

Partner

Client

Partner

Business Partner

Rain Therapeutics

Zentalis Pharmaceuticals

Community Health Network

Country

United States

United States

United States

Subscribe to see more

Subscribe to see more

News Snippet

Rain Therapeutics Announces Collaboration With Tempus For Genomic Analysis In Planned MDM2-Amplified Phase 2 Basket Trial Of RAIN-32

NEWARK , Calif. , June 03 , 2021 -- Rain Therapeutics Inc. , a clinical-stage company developing precision oncology therapeutics , today announced a master program and a genomic analysis platform agreement for comprehensive genomic profiling tests utilizing artificial intelligence and precision medicine company Tempus ' genomic analysis platform .

May 17, 2021 at 7:00 AM EDT. Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update.

Zentera Therapeutics , Zentalis Pharmaceuticals , Inc. ' majority-owned joint venture , filed four Clinical Trial Applications and three have been approved in China to date for ZN-c5 , ZN-c3 , and ZN-c3 in combination .

Community Virtual Care visits available 24/7. COVID-19: Care Options, Visitor Policies & Testing. Community Health Network collaborates with Tempus to personalize cancer care, improve patient health through genomics testing

Community Health Network announced today it is collaborating with Tempus , a leader in precision medicine and artificial intelligence , to improve patient health and outcomes through genomic testing .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

2

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.